Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10288488 | 0.78 | LMNA (0.32) | SMN1; SMN2LMNAMAPTTP53POLB | |
| SCHEMBL469880 | 0.75 | HPGD (0.41) | ALDH1A1MEN1KMT2APOLBHPGD | |
| SCHEMBL508615 | 0.75 | MAPT (0.30) | LMNAMAPTTP53CDK8ACVR1 | |
| SCHEMBL15063888 | 0.73 | KMT2A (0.32) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL469902 | 0.72 | CRHR1 (0.34) | SMN1; SMN2LMNAMAPTTP53POLB | |
| SCHEMBL509911 | 0.72 | — | — | |
| SCHEMBL512824 | 0.72 | CDK8 (0.41) | SMN1; SMN2ALDH1A1LMNAMAPTTP53 | |
| SCHEMBL12481871 | 0.70 | PKM (0.41) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL12481432 | 0.70 | LMNA (0.36) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL466412 | 0.69 | MAPT (0.36) | SMN1; SMN2ALDH1A1LMNAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2406232-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010104217-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | C5, C1S, WEE1 | SMN1; SMN2 2838/4885ALDH1A1 1534/4885LMNA 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.